Clinical Trials
4 results for Kidney/Renal Cancer
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer [PDIGREE]
- Condition: Clear Cell Renal Cell Carcinoma, Metastatic Malignant Neoplasm in Lymph Node, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Soft Tissues, Metastatic Malignant Neoplasm in the Viscera, Sarcomatoid Renal Cell Carcinoma
- Intervention: Drug: Cabozantinib, Biological: Ipilimumab, Biological: Nivolumab, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
- Study ID: NCT03793166
A Therapeutic Trial for Safety and Preliminary Efficacy of the Combination of Axitinib and Seleniomethionine (SLM) for Adult Patients With Advanced Metastatic Clear Cell Renal Cell Carcinoma (CCRCC)
- Condition: Advanced Metastatic Clear Cell Renal Cell Carcinoma (CCRCC)
- Intervention: Drug: Selenomethionine (SLM), Drug: Axitinib, Drug: Selenomethionine (SLM), Drug: Axitinib
- Study ID: NCT02535533
Neoadjuvant AXITINIB and AVELUMAB for Patients With Localized Clear-cell RCC and a Moderate to High Risk
- Condition: Renal Cell Carcinoma
- Intervention: Drug: Axitinib, Drug: Avelumab
- Study ID: NCT03341845
A Pilot Study of Neoadjuvant Combination Spartalizumab and Canakinumab Prior to Radical Nephrectomy in Patients With Localized Clear Cell Renal Cell Carcinoma (SPARC-1 Trial)
- Condition: Carcinoma, Renal Cell
- Intervention: Drug: Spartalizumab, Drug: Canakinumab
- Study ID: NCT04028245